ReviewTrends in cardiovascular medicine2006
Versican degradation and vascular disease.
Review in Trends in cardiovascular medicine, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 96 citations in OpenAlex.
- Vascular Extracellular Matrix in Atherosclerosis.International journal of molecular sciences · 2024Review
- The Contribution of Vascular Proteoglycans to Atherothrombosis: Clinical Implications.International journal of molecular sciences · 2023Review
- Targeting Chondroitin Sulphate Synthase 1 (Chsy1) Promotes Axon Growth Following Neurorrhaphy by Suppressing Versican Accumulation.Molecules (Basel, Switzerland) · 2023Article
- Regional and disease specific human lung extracellular matrix composition.Biomaterials · 2023Article
- Differential Expression and Localization of ADAMTS Proteinases in Proliferative Diabetic Retinopathy.Molecules (Basel, Switzerland) · 2022Article
- Proteolysis: a key post-translational modification regulating proteoglycans.American journal of physiology. Cell physiology · 2022Review
- Defining the versican interactome in lung health and disease.American journal of physiology. Cell physiology · 2022Review
- Stem Cell Based Approaches to Modulate the Matrix Milieu in Vascular Disorders.Frontiers in cardiovascular medicine · 2022Review
- Biomechanical consequences of compromised elastic fiber integrity and matrix cross-linking on abdominal aortic aneurysmal enlargement.Acta biomaterialia · 2021Article
- New Insights into ADAMTS Metalloproteases in the Central Nervous System.Biomolecules · 2020Review
- TRAIL signals, extracellular matrix and vessel remodelling.Vascular biology (Bristol, England) · 2020Review
- Versican-A Critical Extracellular Matrix Regulator of Immunity and Inflammation.Frontiers in immunology · 2020Review
- Article
- Elucidating the role of graft compliance mismatch on intimal hyperplasia using an ex vivo organ culture model.Acta biomaterialia · 2019Article
- A role for proteoglycans in vascular disease.Matrix biology : journal of the International Society for Matrix Biology · 2018Review
- Versican is differentially regulated in the adventitial and medial layers of human vein grafts.PloS one · 2018Article
- Stromal Versican Regulates Tumor Growth by Promoting Angiogenesis.Scientific reports · 2017Article
- Crosstalk Between T Lymphocytes and Lung Fibroblasts: Generation of a Hyaluronan-Enriched Extracellular Matrix Adhesive for Monocytes.Journal of cellular biochemistry · 2017Article
- A Functional Variant of SMAD4 Enhances Thoracic Aortic Aneurysm and Dissection Risk through Promoting Smooth Muscle Cell Apoptosis and Proteoglycan Degradation.EBioMedicine · 2017Article
- Provisional matrix: A role for versican and hyaluronan.Matrix biology : journal of the International Society for Matrix Biology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Versican is an abundant proteoglycan in the blood vessel wall that is increased after vascular injury and accumulates in advanced atherosclerotic plaques. Versican is a large molecule with domains that mediate binding to cytokines, enzymes, lipoproteins, other extracellular matrix molecules, and signaling receptors. There is evidence that versican exists in the normal, as well as the diseased, vessel wall as discrete fragments, which represent these functional domains. We review the literature on versican degradation in vascular tissue and the function of versican domains, all of which suggest that proteolytic modification of versican may have physiologic as well as pathologic implications for the vascular system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.